Leap Therapeutics reports Q2 net loss $17M, cash $90.9M; director Bertagnolli resigns for NCI role

CYPHERPUNK TECHNOLOGIES INC.

2022-Q2 EPS reported -$0.24

Net loss $17.0M in Q2 2022 ($9.5M in Q2 2021); R&D expenses $14.0M vs $7.2M, driven by manufacturing and trial costs.
Cash and equivalents $90.9M at June 30, 2022, providing expected runway into mid-2024.
Initiated Part C of DisTinGuish study (DKN-01 + tislelizumab + chemo) in first-line G/GEJ cancer; also started DeFiance study in second-line CRC.
Director Dr. Monica Bertagnolli resigned effective Aug 12, 2022 to become Director of the National Cancer Institute; no disagreement with company.
Presented initial prostate cancer data at ASCO 2022: in combination cohort, all 6 patients had >50% PSA reduction, 5 with measurable disease had partial response.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Monica Bertagnolli

director

CYPH · CYPHERPUNK TECHNOLOGIES INC.

Effective: 2022-08-12
Filed: August 12, 2022, 7:59 PM ET

On August 11, 2022, Dr. Monica Bertagnolli, a director of the Company, informed the Company that she will be resigning as a director, effective August 12, 2022, as a result of her appointment as the 16th Director of the National Cancer Institute (NCI) by the Biden administration.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Monica Bertagnolli resigned as director at CYPHERPUNK TECHNOLOGIES INC..

Action: resigned
Role: director

Exact text from the filing

On August 11, 2022, Dr. Monica Bertagnolli, a director of the Company, informed the Company that she will be resigning as a director, effective August 12, 2022, as a result of her appointment as the 16th Director of the National Cancer Institute (NCI) by the Biden administration.

View on SEC.gov

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-089676

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.